SOURCE: Insight Pharma Reports

Insight Pharma Reports

May 12, 2016 13:00 ET

New Data on Combination Antibody Therapy for Cancer Treatment

Exclusive Interviews with Symphogen, BioPlan Associates, Lonza, Eureka Therapeutics, & Peregrine Pharma

NEEDHAM, MA--(Marketwired - May 12, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, announces the addition of "Combination Antibody Therapy for Cancer Treatment" to its extensive life science market research reports portfolio.

Recombinant antibodies have been the shining jewels in the firmament of the pharma industry for almost the last two decades. They have returned billions of dollars in sales, and if their performance has not been the unalloyed triumph that was foreseen at their inception, they have, at least in some instances, produced impressive gains in patient response. Today they are one of the most fundamental strategies for treating patients with hematological malignancies and solid tumors. This report explores the next level of therapy, combining antibodies with additional agents.

Included in the report is insight from expert interviews industry leaders:

  • Esper Boel, SVP, head of discovery; Ivan Horak, CSO; and Mads Laustsen, CMO at Symphogen
  • Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
  • Dr. Laurent Ducry, Group Leader Bioconjugates R&D, Lonza, Valais, Switzerland
  • Dr. Cheng Liu, CEO, Eureka Therapeutics
  • Steve King, President, Peregrine Pharma

Exclusive to the Combination Antibody Therapy for Cancer Treatment Report is survey data with industry representatives concerning developments in antibody technologies.

This report explores the next level of therapy, combining antibodies with additional agents, with topic coverage that includes:

  • A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
  • Outlook for combination antibody therapeutics
  • Targeted Antibody Therapeutics & Immuno-Antibody Therapeutics
  • Development and Current Products
  • Combination of Chemotherapy and Immuno-antibody therapeutics
  • Combinations of immune-antibodies
  • Immuno-antibody therapeutics in the marketplace
  • Fusion Antibody Therapeutics
  • Multitargeted and Polyfunctional Antibody Therapeutics
  • Patent Expiration and the Rise of Biosimilars
  • Biosimilar antibodies in the market
  • Deals and the Marketplace

For more information about this report, visit: www.insightpharmareports.com/Combination-Antibody-Therapy-Report

About Insight Pharma Reports (www.insightpharmareports.com)

Insight Pharma Reports, a division of Healthtech Publishing, is the premier life sciences information provider offering unparalleled coverage of key issues in drug discovery and development. The reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research. Insight Pharma Reports provide comprehensive coverage of salient issues in a concise, well-organized format.

About Healthtech Publishing (www.healthtechpublishing.com)

Healthtech Publishing, a division of Cambridge Healthtech Institute, provides the life science communities with business critical intelligence through research reports and digital news, helping decision makers to gain competitive advantage and make strategic decisions. Our portfolio consists of Insight Pharma Reports' vast research reports collection and three niche digital subscription products: Bio-IT World, Clinical Informatics News and Diagnostics World.

Contact Information